Efavirenz Promotes β-Secretase Expression and Increased Aβ$_{1-40,42}$ via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)

Lecia A. M. Brown[1,2], Jingji Jin[1], Darren Ferrell[1,2], Edin Sadic[1], Demian Obregon[3], Adam J. Smith[3], Jun Tan[2,3,4,5], Brian Giunta[1,2,4,5]*

1 Department of Psychiatry and Behavioral Neurosciences, Neuroimmunology Laboratory, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America, 2 Department of Molecular Medicine, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America, 3 Department of Psychiatry and Neurosciences, Rashid Developmental Neurobiology Laboratory, Silver Child Development Center, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America, 4 Center of Excellence for Aging and Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida, Morsani College of Medicine, Tampa, Florida, United States of America, 5 James A. Haley Veterans Administration Hospital, Tampa, Florida, United States of America

Abstract

Efavirenz (EFV) is among the most commonly used antiretroviral drugs globally, causes neurological symptoms that interfere with adherence and reduce tolerability, and may have central nervous system (CNS) effects that contribute in part to HIV associated neurocognitive disorders (HAND) in patients on combination antiretroviral therapy (cART). Thus we evaluated a commonly used EFV containing regimen: EFV/zidovudine (AZT)/lamivudine (3TC) in murine N2a cells transfected with the human "Swedish" mutant form of amyloid precursor protein (SweAPP N2a cells) to assess for promotion of amyloid-beta (Aβ) production. Treatment with EFV or the EFV containing regimen generated significantly increased soluble amyloid beta (Aβ), and promoted increased β-secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not significantly alter these endpoints. Further, EFV or the EFV containing regimen promoted significantly more mitochondrial stress in SweAPP N2a cells as compared to 3TC, AZT, or vehicle control. We next tested the EFV containing regimen in Aβ - producing Tg2576 mice combined or singly using clinically relevant doses. EFV or the EFV containing regimen promoted significantly more BACE-1 expression and soluble Aβ generation while 3TC, AZT, or vehicle control did not. Finally, microglial Aβ phagocytosis was significantly reduced by EFV or the EFV containing regimen but not by AZT, 3TC, or vehicle control alone. These data suggest the majority of Aβ promoting effects of this cART regimen are dependent upon EFV as it promotes both increased production, and decreased clearance of Aβ peptide.

Introduction

There has been considerable growth in patient's receiving combination antiretroviral therapy (cART) in recent years [1]. Up to 50% of long-term HIV-infected patients experience HIV associated neurocognitive disorders (HAND) [2]. Most recently it was shown the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) efavirenz (EFV) is associated with cognitive disorders even in asymptomatic HIV-infected patients [3]. A randomized controlled study [4] found subjects receiving EFV-containing regimens showed less improvement from baseline on instruments examining speed of information processing and executive function than patients not on EFV. Further, patients with preserved immune function on EFV regimens showed greater improvement on Trail-Making Tests A and B and the Wechsler Adult Intelligence Scale digital symbol test after EFV interruption than

the non-EFV control group [5]. EFV has substantial rates of central nervous system (CNS) side effects aside of cognitive impairment including sleep and dreaming disturbances and anxiety [6–8] that interfere with adherence and tolerability as well [9].

Amyloid-beta (Aβ) peptide generation and aggregation as plaques are traditionally known as key events in the development of Alzheimer's Disease (AD; [10–13]). The peptides have been evidenced to be neurotoxic, as they are reported mediators of inflammation [14,15], and oxidative stress [16]. Aβ peptides are produced *via* the amyloidogenic pathway of amyloid precursor protein (APP) proteolysis, which involves the actions of β and γ-secretases [13,17]. Initially, β-secretase (BACE-1) cleaves APP, creating an Aβ-containing carboxyl-terminal fragment known as β-C-terminal fragment (β-CTF) [18]. This proteolysis also

generates an amino-terminal, soluble APP-β (sAPP-β) fragment, which is released extracellularly. Intracellularly, β-CTF is then cleaved by a multi-protein γ-secretase complex that results in generation of the Aβ peptide and a smaller γ-CTF [19,20]. In the human brain Aβ$_{1-40}$ is the predominant form whereas Aβ$_{1-42}$ represents about 10% of Aβ in brain and has a greater propensity to form neurotoxic oligomeric and aggregated species [21].

The rapid, early clinical phase-in of cART required dose de-escalations secondary to toxicities suggested to be related to mitochondrial drug side effects [22]. Mitochondrial dysfunction can result in an elevation of reactive oxygen species (ROS) that in turn promotes amyloidogenic APP processing by promoting BACE-1 activity [18]. Such mitochondrial stress has also been reported occurs in patients taking lamivudine (3TC), zidovudine (AZT) and especially EFV [23–28]; a commonly used cART regimen [29–31]. In light of the increasing life-span's imparted by cART, the mitochondrial promoted by cART [23–27,32–34], and the age associated risk for developing amyloid pathology [35], it is not surprising that a body of epidemiological data suggests significant numbers of long-term HIV survivors are at elevated risk of developing early brain aging in the form of AD like pathology including Aβ deposition [36–42].

As a result, we hypothesized that Aβ pathology may be produced *via* the amyloidogenic pathway of APP proteolysis, which involves the actions of BACE-1 [13] in patients on such regimen and sought to test this with *in vitro* and *in vivo* models. Our results indicate that EFV is the primary antiretroviral in this commonly used EFV containing regimen: EFV/3TC/AZT [29–31] which is responsible for its promotion of Aβ pathology.

Materials and Methods

All animal work was approved by the University of South Florida Institutional Animal Care and Use Committee (IACUC).

Reagents

Aβ$_{1-40}$ and Aβ$_{1-42}$ peptides and control peptide (Aβ$_{40-1}$) were obtained from QCB (Hopkinton, MA) and freshly solubilized in distilled H$_2$O immediately before use. To determine the oligomeric state of Aβ in our assays, Aβ was immunoprecipitated from cell supernatants after incubation with microglia and/or neurons, and Western blot analysis was performed at time points of 12, 24, and 48 hr. Data revealed that both Aβ$_{1-40}$ and Aβ$_{1-42}$, irrespective of the time points assayed, existed as a ladder of SDS-stable oligomers, with a predominant species of ~32 kDa. Immun-Blot polyvinylidene difluoride (PVDF) membranes were purchased from Bio-Rad (Hercules, CA). Tris-buffered saline was obtained from Bio-Rad (Hercules, CA) and luminol reagent was obtained from Pierce Biotechnology. Anti-actin antibody was obtained from Roche. Antiretrovirals were obtained from The National Institutes of Health (NIH) AIDS Research and Reference Reagent Program (Rockville, MD). Regarding dosages administered, cART effects *in vivo* are likely to occur over long- term exposures [43]. Thus, chronic, low dose, *in vivo* effects of any reagent are often very appropriately modeled *in vitro*, by proportionally higher doses of the same reagent, over more acute time frames [43]. For these reasons we used 10 μM cART doses throughout our *in vitro* works and per our previous study [44]. The doses of cART administered *in vivo* were based on based on human clinical therapy [45], the body weight of the mice, the short dosing period of 10 ten days, the administration method being in chow as opposed to intravenous administration, as well as those reported in previous publications: AZT 50 mg/kg [46–48], 3TC 40 mg/kg [47,48], and EFV 15 mg/kg [46,49].

Neuronal Aβ Production Assay

This was performed according to our previous works [44]. Briefly, SweAPP N2a cells were treated with EFV, AZT, and 3TC both alone (10 μM) and in combination (10 μM) for 18 hours. Aβ$_{1-40, 42}$ peptides were detected directly from the conditioned media and quantified in these samples using Aβ$_{1-40, 42}$ ELISA kits (Life Technologies) in accordance with the manufacturer's instructions.

Western immunoblotting

Western blot was performed as described previously [50,51]. Briefly, total protein content was estimated using the Bio-Rad protein assay in strict accordance with manufacturer's directions. Immunoblotting was performed with a primary antibody followed by an anti-mouse HRP-conjugated IgG secondary antibody as a tracer. Primary antibodies used included: 6E10 monoclonal anti-Aβ antibody (Covance, 1:1000), polyclonal Rabbit anti- BACE-1 (Sigma1:1000), C-terminus monoclonal anti-BACE-1 (Millipore 1:1000), and anti-actin antibody (Sigma, 1:1500).

For the *in vivo* studies of Aβ associated pathology we employed our previous methods [50,51]. Left hemispheres of 3 month old transgenic and nontransgenic mouse brains were lysed in ice-cold lysis buffer and aliquots were electrophoretically separated using 16.5% Tris–tricine gels. Electrophoresed proteins were then transferred to PVDF membranes (Bio-Rad), washed in dH$_2$O, then blocked in Tris-buffered saline containing 5% (w/v) non-fat dry milk. Membranes were then hybridized with various primary antibodies followed by washing in dH$_2$O and then incubation for 1 h at ambient temperature with the appropriate HRP-conjugated secondary antibody (1:1000). For both *in vitro* and *in vivo* studies, blots were developed and then assessed densitometrically analyzed using the Fluor-S MultiImager with Quantity One software (Bio-Rad).

Mitochondrial Stress Analysis: Adenosine triphosphate (ATP), mitochondrial membrane potential (MMP), and reactive oxygen species (ROS)

ATP determination was performed using the Invitrogen ATP determination kit (A22066). MMP analysis was performed using a JC-1 (excitation filter 530/25, emission filter 590/35) MMP detection kit (Biotium). Cellular ROS generation was analyzed using 2,7-dichloro dihydrofluorescein diacetate (excitation filter 485/20, emission filter528/20) from the Invitrogen ROS detection kit. For all three analyses of mitochondrial stress, the reagents and reaction mixture were combined according to the supplied protocol. All fluorescence measurements were read using a Biotek Synergy H1 microplate reader.

Microglial Phagocytosis Assay

This was performed according to our previous studies [44,50]. Briefly, primary mouse microglia were treated with "aged" Aβ$_{1-42}$ peptide conjugated with FITC (BioSource Life Technologies^{TM}) with antiretroviral drugs both alone (10 μM) and in combination (10 μM). The total cellular protein of all groups was quantified and adjusted using the Bio-Rad protein assay. Extracellular and cell associated FITC-tagged Aβ was quantified using an SPECTRA-max GEMINI microplate fluorometer (Molecular Devices Corp.) with an emission wavelength of 538 nm and an excitation wavelength of 485 nm. Microglial cells were rinsed 3 times in Aβ-free complete medium, and the media was exchanged with fresh Aβ-free complete medium for 10 min both to allow for removal of non-incorporated Aβ and to promote concentration of the Aβ into phagosomes. The relative mean fluorescence values

for each sample at 37°C and 4°C at the indicated time points were determined by fluorometric analysis. Relative mean values were calculated as: (mean fluorescence value for each sample at 37°C - mean fluorescence value for each sample at 4°C). In this manner, both extracellular and cell associated FITC-labeled Aβ were quantified.

Statistical analysis

All data were normally distributed; therefore, in instances of single mean comparisons, Levene's test for equality of variances followed by *t*-test for independent samples was used to assess significance. In instances of multiple mean comparisons, analysis of variance (ANOVA) was used, followed by *post-hoc* comparison using Bonferonni's method/correction. Alpha levels were set at 0.05 for all analyses. The statistical package for the social sciences release 10.0.5 (SPSS Inc., Chicago, IL, USA) was used for all data analysis.

Results

Epidemiological reports indicate that HAND persists in patients even with good viremic control who take EFV [3]. Previous studies have shown that cART imparts mitochondrial toxicity in the form of elevate ROS [23,24]. A high ROS microenvironment has been shown to promote the activity of BACE-1, a key enzyme the generation of Aβ in the brain [52]. Brain oligomeric [53] and $Aβ_{1-40,42}$ [54] have been correlated with cognitive impairment. Since the EFV containing regimen may promote mitochondrial dysfunction [23,24,27,34,55] which could result in increased BACE-1 activity, we investigated the effect of a commonly used EFV containing cART regimen [29–31] for its ability to upregulate Aβ production *via* activation of BACE-1 and amyloidogenic APP processing and also for its ability to reduce microglial phagocytosis of $Aβ_{1-40,42}$.

BACE-1 is involved in Aβ generation promoted by the EFV containing cART regimen in cultured SweAPP N2a cells (Fig. 1)

Using similar conditions as in our prior investigations [44], SweAPP N2a cells were treated with the EFV containing regimen: 3TC, AZT, EFV or each drug singly at 10 µM in addition to PBS control for 18 hours. $Aβ_{40}$ and $Aβ_{42}$ peptides were then measured in conditioned media from these cells by ELISA (Fig. 1A–C) while BACE-1 expression was measured in cell lysates by Western Blot analysis (Fig. 1D–E). The EFV containing regimen increased $Aβ_{40}$ and $Aβ_{42}$ production in SweAPP N2a cells significantly (**$P<0.05$). Importantly, we found that EFV alone was more potent than the EFV containing regimen in terms of significantly increasing $Aβ_{40}$ and $Aβ_{42}$ production by these cells (***$P<0.001$). Additionally EFV or the EFV containing regimen increased BACE-1 expression in SweAPP N2a cells significantly (***$P<0.001$). These data would suggest that 3TC and/or AZT somehow reduces the toxicity of EFV in terms of promoting amyloidogenic APP processing and that EFV is the primary agent promoting Aβ production in SweAPP N2a cells. There is some evidence to indicate that AZT may indeed have a neuroprotective effect [56–58] which could explain why the EFV containing regimen is less potent in its amyloid producing effects compared to EFV alone.

Cerebral amyloidosis in Tg2576 mice is increased by EFV or the EFV containing cART regimen (Fig 2)

Brain Aβ deposition is a pathognomonic feature of AD [59],and oligomeric Aβ species are thought to be a driving force in AD-type neurodegeneration [60–63]. They may also play a role in HAND development [37–42] The transgenic Tg2576 mouse [64] is a widely used model of cerebral amyloidosis, and we purchased them from Taconic (Germantown, NY) at 8 months of age. They were evaluated for changes in cerebral Aβ after 10 days treatment with each antiretroviral singly or combined as well as vehicle control. Data are represented as mean ± SD with $n = 5$ females per group at 8 months of age. Western blot analysis of brain homogenates revealed significantly increased Aβ species in both the EFV and EFV containing regimen groups (**$p<0.01$ and 0.05 respectively); again suggesting that EFV accelerates cerebral amyloidosis as opposed to having a cumulative effect with 3TC and AZT. Indeed AZT is most likely behind the reduced potency of the EFV containing regimen compared to EFV alone in terms of Aβ pathology in light of reports that it may be neuroprotective [56–58]. Additionally EFV or the EFV containing regimen increased BACE-1 expression in SweAPP N2a cells significantly (***$P<0.001$).

EFV promotes mitochondrial stress in SweAPP N2a cells (Fig. 3)

To determine if EFV or the EFV containing cART regimen could promote mitochondrial stress in an amyloid producing model, SweAPP N2a cells were treated with EFV, 3TC, AZT, or all three antiretrovirals combined in addition to vehicle control (PBS) for 48 hours. We performed three separate assays to determine general mitochondrial function. These included analyses of cellular ATP production, MMP, and ROS production. EFV or the EFV containing regimen were most potent in reducing mitochondrial function. Mitochondria produce approximately 90% of the total cellular ATP in neurons [65]. We therefore first examined ATP levels in SweAPP N2a cells as a measure of mitochondrial function. Cells treated with EFV or the EFV-containing regimen had greatly decreased ATP levels (***$P<0.001$) although the EFV containing regimen had slightly less ATP depletion than EFV alone. Mitochondria from SweAPP N2a cells treated with EFV or the EFV containing regimen showed significantly reduced maximal respiratory rates compared to 3TC or AZT treated SweAPP N2a cells; mirroring the results with the ATP analysis. The MMP is an indicator of electron transport chain function [65].

Mitochondria are the main source of cellular ROS in the brain, thus the rate of ROS reflects the efficiency of mitochondrial function as well [65] (Fig. 3C–F). EFV or the EFV containing regimen caused a large increase in ROS production ($P<0.001$ and $P<0.05$ respectively). AZT and 3TC did not cause a significant rise thus explaining the reduced potency in terms of promoting ROS production of the three drug combination versus EFV alone.

From the three cell-based assays that were utilized to monitor different parameters of mitochondrial function, EFV was identified as the most deleterious compound in our screen of this commonly used cART regimen [29–31]. From all three assays we see that AZT and 3TC reduce this effect promoted by EFV.

Microglial phagocytosis of $Aβ_{1-42}$ peptides is opposed by EFV (Fig. 4)

Amyloid load in the brain is affected not only by production, but also by its clearance from the brain *via* microglia mediated mechanisms [66]. To determine whether the EFV containing regimen could affect microglial clearance of Aβ and further promote amyloidosis, we performed a phagocytosis assay with primary mouse microglia in the presence of EFV, 3TC, AZT or all three antiretrovirals combined in addition to PBS control.

Figure 1. EFV or EFV/3TC/AZT treatment promotes Aβ generation in cultured neuronal cells *via* BACE-1 activation *in vitro*. Aβ species were analyzed in cell lysates from SweAPP N2a cells (**A**) by ELISA. Data are represented as the mean ± of a percentage of Aβ peptides secreted 24 h after 3TC, AZT, EFV, or 3TC/EFV/AZT administration, relative fold over control (PBS treated). Significant increases in Aβ were observed in EFV or EFV/3TC/AZT treated cells were observed compared to control (***P<0.001 and **P<0.05 respectively by ANOVA). (**B**) Western blot (6E10 antibody) of conditioned media shows increased oligomeric Aβ species vs. s-APP-α (control) in the EFV or EFV/3TC/AZT treated cells (***P<0.001 and **P<0.05 respectively). (**D**) BACE-1 expression in cultured media revealed significant differences between EFV or EFV/3TC/AZT treated cells compared to untreated control (***P<0.001). β-actin is used for the internal loading control. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0095500.g001

Following detection of FITC-tagged Aβ$_{1-42}$ in extracellular and cell associated fractions, we again found that EFV or the EFV containing regimen inhibited microglial phagocytosis/clearance. These two treatments significantly inhibited microglial phagocytosis of Aβ$_{1-42}$ peptides as determined by high levels of peptide remaining in the cultured media (extracellular) (*p<0.001* and *p<0.05 respectively*). In addition, EFV or the EFV containing regimen tested also significantly reduced levels of phagosomal (cell associated) Aβ$_{1-42}$ (*p<0.001* and *p<0.05 respectively*). Also, when comparing cell associated Aβ$_{1-42}$ levels of the EFV compared to the three drug combination to levels of these compound alone, the differences suggest the major reduction in phagocytosis is imparted by EFV and the addition of the other two antiretrovirals of the regimen are not additive in nature. Importantly, when comparing the levels of extracellular Aβ$_{1-42}$ to that of cell associated we can see that the phagocytosis/clearance profiles are relatively congruent for each treatment condition. That is to say, when a given treatment maintains high levels of extracellular Aβ$_{1-42}$, the corresponding cell associated levels are relatively low. Not only does this apparent relationship between extracellular and cell associated Aβ$_{1-42}$ levels confirm the accuracy of the assay, but also furthers the overall significance of the inhibition of microglial phagocytosis by the antiretrovirals [44].

Discussion

Here, we elucidate a potential mechanism whereby EFV may have neurotoxic effects *via* promotion of brain Aβ. As shown in Figure 5, our present study has led to the proposed mechanism of neurotoxicity in which EFV promotes an increase in Aβ *in vitro* and

in vivo on both the production and clearance fronts *via* its inhibition of proper MMP resulting in reduced ATP stores and thus a high ROS environment in the CNS. It is proposed that EFV induced high ROS microenvironments (Fig. 3) in the CNS promote BACE-1 APP processing ([18]; Fig. 1) and also inhibits microglial phagocytic functions (Fig. 4; [67]). These events in turn all promote production of Aβ species.

EFV has been associated with serious adverse reactions, most of which can in part be attributed directly or indirectly to dysfunction of mitochondria [22–25,33]. We found that EFV, or the EFV containing regimen consistently and significantly promoted mitochondrial oxidative stress in the form of reduced cellular ATP stores (Fig. 3A) and MMP (Fig. 3B), as well as increased release of ROS (Fig. 3C–F). These observations suggest the mitochondrial stress imparted by this cART regimen is largely dependent upon EFV and that 3TC and/or AZT may have some protective effect. Indeed there is some evidence that the latter antiretroviral may help to preserve cognitive function [56–58]

Reactive microgliosis can be associated with the formation of microglial phenotypes that are unfavorable to phagocytic activities [68]. ROS are an important signal for cellular activation and proliferation. Over the long term lead to microglial dysfunction, rendering the phagocytes unable to perform their vital clearance functions [68]. This may underlie the reduced microglial phagocytosis of Aβ observed in microglia treated with EFV or the EFV containing regimen (Fig. 4).

Several lines of epidemiological evidence signal a role for Aβ in HAND development while some studies have not yet fully implicated over production of the protein as a contributor to

Figure 2. EFV/3TC/AZT increases soluble Aβ levels in Tg2576 mice *via* BACE-1 activation *in vivo*. (**A**) $A\beta_{40, 42}$ peptides were analyzed in brain homogenates from 8 month old Tg2576 mice by ELISA (n = 5 mice for each group). One-way ANOVA followed by *post hoc* comparison revealed significant differences between control (Tg2576mice treated with PBS) and EFV or EFV/3TC/AZT -treated Tg2576 mice ($P<0.001$ and *0.05* respectively with n = 5 mice/group). (**B**) Western Blot of brain homogenates using anti-$A\beta_{1-17}$ antibody (6E10) shows total APP and a bands corresponding to soluble Aβ oligomer species. β-actin was an internal control. A *t-test* revealed significant differences in soluble Aβ species between EFV-treated compared to 3TC/AZT/EFV, 3TC or AZT treated Tg2576 mice ($P<0.01$) (**C**) BACE-1 expression in brain homogenate of Tg2576 mice significantly was increased in EFV or EFV/3TC/AZT -treated Tg2576 mice ($P<0.001$).
doi:10.1371/journal.pone.0095500.g002

Figure 3. cART treatment of SweAPP N2a cells promotes mitochondrial dysfunction. (*A*) *ATP levels are reduced in EFV or EFV/3TC/AZT treated SweAPP N2a neuron cells:* SweAPP N2a cells were grown with 10 µM of each medication or all three medications combined for 48 h. We found a significant decrease in ATP levels in cells treated with EFV or 3TC/AZT/EFV (***$P<0.001$). (B)MMP is reduced in EFV or EFV/3TC/AZT SweAPP N2a cells: In accord with reduced ATP levels we found a similar reduction in MMP in the EFV or EFV/3TC/AZT treated groups (***$P<0.001$) (C–F) ROS levels are increased in EFV or EFV/3TC/AZT treated SweAPP N2a cells: EFV-treated primary neuron cells have significantly higher ROS contents (**$P<0.001$) after incubation for 60 min than untreated primary neuron. (C–E)The average relative fluorescence units of DCFDA in neurons from each treatment group as indicated by the mean ± standard deviations (D, F) The ROS content in the antiretroviral treatment is expressed as % RFU ± standard deviations for each group compared to untreated control primary neuron cells (100%). (*$P<0.05$, *** $P<0.001$).
doi:10.1371/journal.pone.0095500.g003

Figure 4. EFV/3TC/AZT inhibits microglial phagocytosis of Aβ$_{1-42}$ peptide. (A) Primary microglia (1×10^5 cells/well in 24-well tissue culture plates) were treated with aged FITC tagged Aβ$_{1-42}$ (50 nM) in complete medium for 60 min with antiretroviral medications (10uM) combined or singly as indicated, or PBS (control). As a control for nonspecifically incorporated Aβ, microglial cells were incubated at 4°C with the same treatment followed by DAPI staining. EFV or 3TC/AZT/EFV inhibited microglia-colocalization by fluorescence microscopy. Green indicates Aβ$_{1-42}$ positive; blue indicates microglia nuclei. Addition of heat inactivated HIV-1 Tat yielded similar results as vehicle control (data not shown) (B) Cell supernatants and lysates were analyzed for extracellular (top) and cell associated (bottom) FITC-Aβ using a fluorimeter. Data are represented as the relative fold of mean fluorescence change (mean ± SD), calculated as the mean fluorescence for each sample at 37°C divided by mean fluorescence at 4°C ($n = 6$ for each condition presented). One-way ANOVA followed by *post-hoc* comparison showed a significant difference between EFV (***$P<0.001$) or EFV/3TC/AZT (**$P<0.05$) but not 3TC or AZT compared to control.
doi:10.1371/journal.pone.0095500.g004

HAND. It is known that pathological similarities exist between HAND and AD [37–42]. The latter is more so characterized by extracellular deposits of Aβ$_{1-42}$ in the form of plaques and aggregations of microtubule-associated tau yielding neurofibrillary tangles (NFT). In contrast, with HIV infection, the plaques are more diffuse [38] rather than neuritic [41].

Cerebrospinal fluid (CSF) biomarkers can mirror pathogenic cerebral amyloid deposition. Decreased CSF Aβ$_{1-42}$ and increased CSF tau can differentiate symptomatic AD participants and cognitively normal individuals at high risk for symptomatic AD from cognitively normal individuals at low risk for symptomatic AD [69,70]. In that regard, at least some HAND patients have CSF Aβ$_{1-42}$ values comparable to symptomatic AD individuals, that is, reduced [34,41]. This is salient because reductions in CSF Aβ$_{42}$ have been found in almost all individuals with increased fibrillar amyloid deposition within the brain as assessed with positron emission tomography (PET) amyloid binding of N-methyl-[11C]2-(4-methylaminophenyl)-6-hydroxybenzothiazole (^{11}C-PiB) [71–73]. Likewise, AIDS dementia complex (ADC) patients had significantly decreased CSF Aβ$_{1-42}$ and increased total and phospho (t-tau and p-tau respectively) concentrations similar to AD [38]. Achim and colleague's (2009) reported increased Aβ by both autopsy examination and PET imaging of HIV patients. Specifically, cases with HIV encephalitis (HIV-E) were about twice as likely to have amyloid detected (72%) than HIV+ patients without HIV-E (38%; [37]). In the same year Clifford and colleagues reported Aβ$_{1-42}$ measurements in CSF of

cognitively impaired patients with HIV were similarly reduced as in in patients with mild dementia of the Alzheimer type (DAT). Normal or slightly depressed CSF tau and p-tau measurements distinguished these patients with HAND from patients with DAT [42].

Further analysis as to why low CSF Aβ$_{1-42}$ in patients with HAND is needed. However, there are several reasons which may explain altered Aβ metabolism in HIV disease [42] in addition to the data presented in this report. First, HIV-1 transactivator of transcription (Tat) protein may compete with APP and/or apolipoprotein E (an Aβ chaperone) for binding to the low density lipoprotein receptor related protein (LRP), thus inhibiting LRP mediated clearance of Aβ from brain interstitial fluid to periphery [74]. Second, APP cleavage products (sAPPα and sAPPβ) have been reported to be reduced in the CSF of patients with HAND compared to those with DAT or HIV-negative controls, with sAPPα (a neurotrophic protein) showing a slight decline in the asymptomatic HIV state [75].

In 2010 Ances and colleagues reported cognitively unimpaired HIV+ participants, even with low CSF Aβ$_{1-42}$ (<500 pg/mL), did not have (11)C-PiB parameters suggesting brain fibrillar amyloid deposition. This dissimilarity between cognitively unimpaired HIV+ and preclinical AD may reflect differences in Aβ$_{1-42}$ production and/or formation of diffuse plaques [76]. This same group, in 2012, reported symptomatic AD patients were significantly older, had significantly lower CSF Aβ$_{1-42}$, and had significantly higher CSF tau levels than other groups. Regardless

Figure 5. Proposed mechanism of EFV neurotoxicity. Our present work suggests that EFV promotes an increase in Aβ *in vitro* and *in vivo* on both the production and clearance fronts *via* its inhibition of neuronal MMP resulting in reduced ATP stores and thus a high ROS environment in the CNS. Previous studies indicate such high ROS microenvironments in the CNS promote BACE-1 APP processing and also inhibit microglial Aβ clearance functions. These events in turn all promote production of Aβ species. (*Note: Red arrows = inhibition, Green arrows = promotion).
doi:10.1371/journal.pone.0095500.g005

of degree of impairment, HIV patients did not have increased ^{11}C-PiB [77]. Possible reasons for the absence of ^{11}C-PiB in HIV patients are: 1) decreased Aβ$_{1-42}$ production secondary to decreased synaptic activity, 2) increased intraneuronal Aβ$_{1-42}$ deposition that is undetectable by ^{11}C-PiB [37]; and/or 3) increased Aβ$_{1-42}$ brain deposition but in a more diffuse, non-fibrillar form that is undetectable by ^{11}C-PiB [36,39]. Future longitudinal examinations within older HIV+ participants are required to determine if diffuse or oligomeric forms could with time subsequently become fibrillar (^{11}C-PiB positive) deposits [38,42]. Our findings reinforce the importance of understanding the effects of cART on amyloid metabolism since EFV could contribute to the neurological complications that are associated with HIV infection seen clinically [3–9].

The current research has several strengths and weaknesses. Regarding the former, we observed consistent findings in both *in vitro* and *in vivo* model systems in that EFV or the EFV containing regimen caused increase amyloidogenic APP processing as a function of increased BACE-1 expression and decreased microglial clearance of Aβ. Additionally, we find the level of mitochondrial dysfunction imparted by each antiretroviral medication correlates consistently with the increased level of BACE-1 expression and Aβ production, and the decreased microglial phagocytosis of Aβ peptide. Second our results coincide with other reports indicating the mitochondrial toxicity of antiretrovirals [23–27,32–34], and reports that increased ROS can result in increased BACE-1 activity [22].

This report has limitations as well. First, it describes a mechanism for a subset of HAND cases since not all HIV infected individuals are taking EFV or an EFV containing regimen. It should be noted that in the present study, we did not investigate the plasma or CSF concentrations of antiretrovirals or their metabolites. However, all three drugs seem to have good CNS penetration [22,78,79], which could support the the neurologic symptoms [3,5,8] noted by others.

In sum, our present work suggests that EFV promotes an increase in A*β* on both the production and clearance fronts through oxidative stress. We hypothesize that a disrupted MMP with resultant lowered neuronal ATP stores promotes a high level of ROS. In turn, this can both promote BACE-1 activity and impair microglial clearance mechanisms. If this mouse model translates to the clinical syndrome, then a pharmacotherapeutic strategy aimed at opposing the EFV-mediated reduced microglial A*β* clearance and/or EFV-mediated neuronal A*β* over production *via* BACE-1 should be beneficial to prevent or treat HAND.

Acknowledgments

Author Contributions

Conceived and designed the experiments: BG. Performed the experiments: LAMB JJ DF BG. Analyzed the data: JJ JT BG. Contributed reagents/materials/analysis tools: BG JT. Wrote the paper: BG AS DO ES.

References

1. Schouten EJ, Jahn A, Ben-Smith A, Makombe SD, Harries AD, et al. (2011) Antiretroviral drug supply challenges in the era of scaling up ART in Malawi. J Int AIDS Soc 14 Suppl 1: S4.
2. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3–16.
3. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, et al. (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76: 1403–1409.
4. Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, et al. (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50: 920–929.
5. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, et al. (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. Aids 21: 1915–1921.
6. Velasco M, Pareja JA, Losa JE, Valverde JF, Espinosa A, Gujarro C Dream changes following initiation of efavirenz treatment. Med Clin (Barc) 136: 103–105.
7. Waters L, Fisher M, Winston A, Higgs C, Hadley W, et al. (2001) A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25: 65–71.
8. Romao PR, Lemos JC, Moreira J, de Chaves G, Moretti M, et al., (2011) Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotox Res 19: 73–80.
9. Wintergerst U, Hoffmann F, Jansson A, Notheis G, Huss K, et al. (2008) Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 61: 1336–1339.
10. Sambamurti K, Greig NH, Lahiri DK (2002) Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1: 1–31.
11. Golde TE, Eckman CB, Younkin SG (2000) Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 1502: 172–187.
12. Huse JT, Doms RW (2000) Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. Mol Neurobiol 22: 81–98.
13. Selkoe DJ (1996) Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harb Symp Quant Biol 61: 587–596.
14. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 188: 431–438.
15. Suo Z, Tan J, Placzek A, Crawford F, Fang C, et al. (1998) Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 807: 110–117.
16. Murakami K, Irie K, Ohigashi H, Hara H, Nagao M, et al. (2005) Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. J Am Chem Soc 127: 15168–15174.
17. Schenk D, Games KD, McConlogue L (1995) The potential utility of transgenic mice harboring beta-amyloid precursor protein. Neurobiol Aging 16: 711–713; discussion 715–718.
18. Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci U S A 96: 11049–11053.
19. Steiner H, Capell A, Haass C (1999) Proteolytic processing and degradation of Alzheimer's disease relevant proteins. Biochem Soc Trans 27: 234–242.
20. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, et al. (1997) Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem 272: 3590–3598.
21. Jacobsen JS, Reinhart P, Pangalos MN (2005) Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2: 612–626.
22. Cossarizza A, Moyle G (2004) Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 18: 137–151.
23. Apostolova N, Blas-Garcia A, Esplugues JV (2011) Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition. Trends Pharmacol Sci 32: 715–725.
24. Apostolova N, Blas-Garcia A, Esplugues JV (2011) Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Des 17: 2130–2144.
25. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV (2011) Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 54: 1009–1019.
26. Blas-Garcia A, Esplugues JV, Apostolova N (2011) Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr Med Chem 18: 2186–2195.
27. Blas-Garcia A, Apostolova N, Esplugues JV (2011) Oxidative stress and mitochondrial impairment after treatment with anti-HIV drugs: clinical implications. Curr Pharm Des 17: 4076–4086.
28. Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic Biol Med 50: 801–810.
29. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095–2106.
30. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341: 1865–1873.
31. Hirschel B, Calmy (2008) A Initial treatment for HIV infection—an embarrassment of riches. N Engl J Med 358: 2170–2172.
32. Apostolova N, Gomez-Sucerquia LJ, Alegre F, Funes HA, Victor VM, et al. (2013) ER stress in human hepatic cells treated with Efavirenz: mitochondria again. J Hepatol 59: 780–789.
33. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV (2011) Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. Autophagy 7: 1402–1404.
34. Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales JM, et al. (2010) Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52: 115–125.
35. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Sr., Diaz-Arrastia R, et al. (2010) Risk factors for beta-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol 2013; 70: 600–606.
36. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111: 529–538.
37. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E (2009) Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol 4: 190–199.
38. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L (2005) CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 65: 1490–1492.
39. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, et al. (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19: 407–411.
40. Alisky JM (2007) The coming problem of HIV-associated Alzheimer's disease. Med Hypotheses 69: 1140–1143.
41. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 65: 29–33.
42. Clifford DB, Fagan AM, Holtzman DM, Morris JC, Teshome M, et al. (2009) CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 73: 1982–1987.
43. Kiebala M, Polesskaya O, Yao Z, Perry SW, Maggirwar SB (2010) Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. PLoS One5: e11875.
44. Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, et al. (2011)Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4: 23.
45. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, et al. (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20: 675–684.
46. Chandra S, Murthy SN, Mondal D, Agrawal KC (2009) Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats. Can J Physiol Pharmacol 87: 300–309.
47. Torres SM, Divi RL, Walker DM, McCash CL, Carter MM, et al. (2010) In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue. Cardiovasc Toxicol 10: 87–99.
48. Torres SM, Divi RL, Walker DM, McCash CL, Carter MM, et al. (2010) In utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue. Cardiovasc Toxicol 10: 87–99.
49. Balani SK, Kauffman LR, deLuna FA, Lin JH (1999) Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab Dispos 27: 41–45.
50. Giunta B, Hou H, Zhu Y, Rrapo E, Tian J, et al. (2009) HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol 2: 433–443.
51. Giunta B, Hou H, Zhu Y, Salemi J, Ruscin A, et al. (2010) Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 471: 134–138.
52. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, et al. (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104: 683–695.
53. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79–84.

54. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, et al. (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64: 354–362.

55. Gomez-Sucerquia LJ, Blas-Garcia A, Marti-Cabrera M, Esplugues JV, Apostolova N (2012) Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. Antiviral Res 94: 232–241.

56. Pizzo PA, Eddy J, Falloon J, Balis FM, Murphy RF, et al. (1988) Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 319: 889–896.

57. Rausch DM, Heyes M, Eiden LE (1994) Effects of chronic zidovudine administration on CNS function and virus burden after perinatal SIV infection in rhesus monkeys. Adv Neuroimmunol 4: 233–237.

58. Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, et al. (1988) Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 319: 1573–1578.

59. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3: 75–80.

60. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, et al. (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28: 4231–4237.

61. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535–539.

62. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30: 552–557.

63. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, (2005) The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33: 1087–1090.

64. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99–102.

65. Dragicevic N, Smith A, Lin X, Yuan F, et al. (2011) Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction. J Alzheimers Dis 26: 507–521.

66. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, et al. (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 29: 4252–4262.

67. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969.

68. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, et al. (2008) Hyman BT Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451: 720–724.

69. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68: 903–912.

70. Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O'Brien RJ, et al. (2011) Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol 68: 113–119.

71. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371–380.

72. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, et al. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65: 176–183.

73. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, et al. (2009) Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65: 927–934.

74. Liu Y, Jones M, Hingtgen CM, Bu G, Laribee N, et al. (2000) Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med 6: 1380–1387.

75. Gisslen M, Krut J, Andreasson U, Blennow K, Cinque P, et al. (2009) Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 9: 63.

76. Ances BM, Christensen JJ, Teshome M, Taylor J, Xiong C, A et al. (2010) Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology 75: 111–115.

77. Ances BM, Benzinger TL, Christensen JJ, Thomas J, Venkat R, et al. (2012) 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 69: 72–77.

78. Wynn HE, Brundage RC, Fletcher CV (2002) Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16: 595–609.

79. Gibbs JE, Gaffen Z, Thomas SA (2006) Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study. J Pharmacol Exp Ther 317: 746–751.